Somite is building the blueprints to create any cell type for any person. We call it DeltaStem, our foundation model for the human cell. Our proprietary capsule technology allows us to generate cell signaling data 1,000x faster and more efficiently than current methods, accelerating discovery and optimization of cell production for treatment of diseases like type 1 diabetes, osteoarthritis, and DMD. DeltaStem allows us to reliably generate previously inaccessible cell types for the first time, unlocking a foundry of human spare parts. To scale DeltaStem and bring it into therapeutics, we’re excited to share that we’ve raised over $47M in Series A funding. Our round was led by Khosla Ventures, with participation from SciFi VC, the Chan Zuckerberg Initiative, Fusion Fund, Ajinomoto Group Ventures, Pitango HealthTech, TechAviv, Harpoon Ventures, along with angel investors such as Dr. R. Martin Chavez (former Chairman of Recursion), and Fidji Simo (outgoing CEO of Instacart and incoming CEO of Applications at OpenAI). Somite was founded and is led by a team of AI entrepreneurs and developmental biologists: Dr. Micha Breakstone, a repeat AI entrepreneur, Dr. Jonathan Rosenfeld, leader of the Fundamental AI Group at MIT, and a distinguished group of scientific co-founders representing institutions like Harvard Medical School and the National Academies of Science and Medicine. We look forward to collaborating with strategic partners who share our vision of leveraging AI for a new age in human repair. Reach out: somite.ai